Management volunteers specific, checkable numbers about the near future — quantified forward commitments it could visibl
The model's full reasoning — Q4 2022 call → NOWe need answer YES/NO. Need evaluate based on transcript. Need determine if management volunteers specific checkable numbers/dates about near term, step-up, commitments. Let's parse. Transcript includes management statements. Key: "20 in '25 program" plan to have 20 drug candidates in clinical trials or market in 2025. That's a specific number but distant 2025, not within roughly next year? Current fiscal 2022 ended Sep 2022, call Nov 2022. Near term within next year = by late 2023. 20 in 2025 is multi-year, not near-term. But they also give specific near-term dates: "expect to report topline data from Phase 2 SEQUOIA ... at same time provide guidance on Phase 3 design" "Takeda submitted Phase 3 protocol ... waiting feedback" "expect Takeda receive feedback shortly" "Takeda still on schedule to begin Phase 3 in first quarter 2023" "we can have update publicly on SEQUOIA and guidance on Phase 3 prior to that." That's a dated start (Phase 3 in Q1 2023) but no size attached? It's a commitment to begin Phase 3. Is that a step-up? It is a new Phase 3, but not quantified in terms of patients. However, "Phase 3 study" is a specific activity, but no number of patients. The question asks "specific, checkable numbers or dates about what company's own business will do in near term — quantified forward commitments concrete enough investors can verify." Dates count? It says "numbers or dates" and "quantities, counts, levels, or dates that could visibly be hit or missed." So dates can be commitments. But need step-up? Starting Phase 3 is a step-up from current? Maybe. Other near-term: "We expect to be able to provide interim data publicly in first half of 2023" for ARO-RAGE and ARO-MUC5AC. That's a date, but not a quantified outcome. "ARO-C3 ... expect to have interim knockdown and safety data in first half of 2023." "expect to announce next cell type in first half of 2023." These are dates, not quantities. Are they commitments? They are volunteered. But do they describe step-up? They are milestones, not necessarily business activity level. Financial: "We expect our operating cash burn to be $70 million to $90 million per quarter in fiscal 2023 and capital expenditures up to $200 million." That's financial guidance, not step-up? It's a range, but not revenue/EPS. It's a forward commitment? It's routine guidance? It's not a step-up in business activity.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| RCEL | AVITA Medical, Inc. | Q1 2024 | 2024-05-14 | F |
| ERO | Ero Copper Corp. | Q1 2024 | 2024-05-10 | A |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| WEC | WEC Energy Group, Inc. | Q1 2024 | 2024-05-01 | A |
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| ASM | Avino Silver & Gold Mines Ltd. | Q4 2023 | 2024-03-21 | C+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| GPRE | Green Plains Inc. | Q4 2023 | 2024-02-07 | F |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| CMG | Chipotle Mexican Grill, Inc. | Q3 2023 | 2023-10-27 | B+ |
| DXLG | Destination XL Group, Inc. | Q2 2023 | 2023-08-24 | D |
| IMAX | IMAX Corporation | Q2 2023 | 2023-07-26 | B+ |
| GGR | Gogoro Inc. | Q1 2023 | 2023-05-11 | D |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SLDP | Solid Power, Inc. | Q1 2023 | 2023-05-08 | C+ |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| CIG | Companhia Energética de Minas Gerais | Q3 2022 | 2022-11-16 | C+ |
| CHUY | Chuy's Holdings, Inc. | Q3 2022 | 2022-11-05 | C+ |
| TWO | Two Harbors Investment Corp. | Q2 2022 | 2022-08-04 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| SQM | Sociedad Química y Minera de Chile S.A. | Q1 2022 | 2022-05-19 | C+ |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| SLQT | SelectQuote, Inc. | Q2 2022 | 2022-02-07 | F |
| HNRG | Hallador Energy Company | Q3 2021 | 2021-11-09 | C+ |
| FFWM | First Foundation Inc. | Q3 2021 | 2021-10-26 | B |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| PRPO | Precipio, Inc. | Q3 2018 | 2018-11-19 | D |
| WES | Western Midstream Partners, LP | Q3 2018 | 2018-10-31 | D |
| MAS | Masco Corporation | Q3 2018 | 2018-10-30 | C |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| ASND | Ascendis Pharma A/S | Q1 2018 | 2018-05-30 | C+ |
| CLMT | Calumet Specialty Products Partners, L.P | Q1 2018 | 2018-05-16 | C+ |
| ITCI | Intra-Cellular Therapies, Inc. | Q4 2017 | 2018-03-01 | D |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| BCE | BCE Inc. | Q2 2017 | 2017-08-05 | B+ |
| GPOR | Gulfport Energy Corporation | Q4 2016 | 2017-02-14 | A |
| PSX | Phillips 66 | Q4 2016 | 2017-02-03 | C+ |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
TWO · Q2 2022 → YESThe question is about whether management volunteers specific, checkable numbers or dates about the company's own business in the near term that show a step-up, grounded in things they can already see....YES The transcript shows management volunteering a concrete, checkable commitment on the RoundPoint acquisition: they expect incremental annual pre-tax earnings of approximately $20 million once the portfolio is fully transferred (with Mary Riskey later confirming $0.45 per share after-tax accretion). They also state they will begin transitioning loans to Round Point as a subservicer later this year and expect the acquisition to close in 2023. These are presented as owned expectations tied to the in-house servicing model they are already executing, describing a clear step-up in earnings and operational activity above the current subservicing level.
CUBI · Q3 2018 → YESThe question is about whether management volunteers specific, checkable numbers or dates about the company's own business in the near term, presenting them as commitments for a step-up from current le...YES Management volunteers concrete, checkable commitments for the near term (next 12–18 months) that describe a clear step-up from current levels and are grounded in things already in motion or in hand. Examples include: - NIM target of 2.75% within 12–18 months, explicitly tied to 3–4 rate hikes and the $495 million securities sale plus $500 million borrowings repayment already executed. - $600 million core-franchise deposit growth + $500–600 million CB digital + $500 million BankMobile white-label deposits next year, building on the $1.
ADPT · Q4 2022 → YESThe question is: Does management volunteer specific, checkable numbers or dates about what the company's own business will do in the near term — quantified forward commitments concrete enough that inv...YES Management volunteers concrete, checkable commitments for 2023 that describe a clear step-up: full-year revenue of $205–215 million (versus $185.3 million in 2022), clonoSEQ test volumes growing more than 50% from the current base, MRD pharma milestones in the mid to high-single-digit millions, community business reaching 20% of total revenue (from 15% currently), and 2023 OpEx (including cost of revenue) slightly below the 2022 level of $385.5 million, with average quarterly cash burn of $40 million.